These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32456983)

  • 1. Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis.
    Manzano A; Eskytė I; Ford HL; Bekker HL; Potrata B; Chataway J; Schmierer K; Pepper G; Meads D; Webb EJ; Pavitt SH
    Patient Educ Couns; 2020 May; ():. PubMed ID: 32456983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.
    Eskyte I; Manzano A; Pepper G; Pavitt S; Ford H; Bekker H; Chataway J; Schmierer K; Meads D; Webb E; Potrata B
    Mult Scler Relat Disord; 2019 Jan; 27():370-377. PubMed ID: 30476873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "I'm walking into the unknown": Qualitative insights into how emotions and lived experience related to multiple sclerosis diagnosis impact on decisions to pursue disease modifying treatment.
    Carey G; Wilson N; Janssen J; Chohan A; Rog D; Roddam H
    Mult Scler Relat Disord; 2022 Feb; 58():103464. PubMed ID: 34952250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.
    Sippel A; Riemann-Lorenz K; Scheiderbauer J; Kleiter I; Morrison R; Kofahl C; Heesen C
    BMC Health Serv Res; 2021 Oct; 21(1):1141. PubMed ID: 34686166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.
    Col NF; Solomon AJ; Alvarez E; Pbert L; Ionete C; BerriosMorales I; Chester J; Kutz C; Iwuchukwu C; Livingston T; Springmann V; Col HV; Ngo LH
    Mult Scler Relat Disord; 2023 Dec; 80():105092. PubMed ID: 37931489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
    Duddy M; Wilkinson C; Medhurst S; Rhys K
    Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
    Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
    Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis.
    Bansback N; Chiu JA; Metcalfe R; Lapointe E; Schabas A; Lenzen M; Traboulsee A; Lynd LD; Carruthers R
    Mult Scler J Exp Transl Clin; 2021; 7(3):20552173211029966. PubMed ID: 34350027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
    Lenz F; Harms L
    Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Efficacy Disease-Modifying Therapies in People with Relapsing-Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions.
    Maurino J; Sotoca J; Sempere ÁP; Brieva L; López de Silanes C; Caminero AB; Terzaghi M; Gracia-Gil J; Saposnik G
    Patient; 2021 Mar; 14(2):241-248. PubMed ID: 32975737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health Economic Impact of Software-Assisted Brain MRI on Therapeutic Decision-Making and Outcomes of Relapsing-Remitting Multiple Sclerosis Patients-A Microsimulation Study.
    Sima DM; Esposito G; Van Hecke W; Ribbens A; Nagels G; Smeets D
    Brain Sci; 2021 Nov; 11(12):. PubMed ID: 34942872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral disease modifying therapies - A game changer for treatment decision in untreated patients with RRMS and CIS? - A swiss single center cross-sectional study.
    Finkener S; Achtnichts L; Cervenakova M; Nedeltchev K; Findling O
    Mult Scler Relat Disord; 2022 Dec; 68():104396. PubMed ID: 36544325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
    Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
    J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
    Jonker MF; Donkers B; Goossens LMA; Hoefman RJ; Jabbarian LJ; de Bekker-Grob EW; Versteegh MM; Harty G; Wong SL
    Med Decis Making; 2020 Feb; 40(2):198-211. PubMed ID: 32065023
    [No Abstract]   [Full Text] [Related]  

  • 19. Factors influencing multiple sclerosis disease-modifying treatment prescribing decisions in the United Kingdom: A qualitative interview study.
    Cameron E; Rog D; McDonnell G; Overell J; Pearson O; French DP
    Mult Scler Relat Disord; 2019 Jan; 27():378-382. PubMed ID: 30500689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.